Abstract
Alpha-1 antitrypsin (AAT) is the most abundant proteinase inhibitor within the circulation and AAT deficiency is a genetic disorder characterised by serum levels of less than 11μmol/L. The Z mutation is the most common AAT allele associated with the disease and causes the most severe plasma deficiency, as the mutant protein polymerizes and accumulates within the endoplasmic reticulum of hepatocytes. The retained polymers are associated with cirrhosis and reduced serum levels of AAT contribute to the development of chronic pulmonary disease in AAT deficient individuals. This article will review the importance of AAT as a serine anti-protease, the clinical manifestations of AAT deficiency and specific treatment of the disease. Current therapies including AAT replacement and treatment with synthetic or alternative protease inhibitors are reviewed, along with possible future therapies including those focusing on targeting AAT polymer formation or based on gene therapy.
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title:New Strategies in Drug Development Focusing on the Anti-Protease- Protease Balance in Alpha-1 Antitrypsin Deficiency
Volume: 9 Issue: 4
Author(s): Emer P. Reeves, Sonya Cosgrove, David A. Bergin, Catherine M. Greene and Noel G. McElvaney
Affiliation:
Abstract: Alpha-1 antitrypsin (AAT) is the most abundant proteinase inhibitor within the circulation and AAT deficiency is a genetic disorder characterised by serum levels of less than 11μmol/L. The Z mutation is the most common AAT allele associated with the disease and causes the most severe plasma deficiency, as the mutant protein polymerizes and accumulates within the endoplasmic reticulum of hepatocytes. The retained polymers are associated with cirrhosis and reduced serum levels of AAT contribute to the development of chronic pulmonary disease in AAT deficient individuals. This article will review the importance of AAT as a serine anti-protease, the clinical manifestations of AAT deficiency and specific treatment of the disease. Current therapies including AAT replacement and treatment with synthetic or alternative protease inhibitors are reviewed, along with possible future therapies including those focusing on targeting AAT polymer formation or based on gene therapy.
Export Options
About this article
Cite this article as:
P. Reeves Emer, Cosgrove Sonya, A. Bergin David, M. Greene Catherine and G. McElvaney Noel, New Strategies in Drug Development Focusing on the Anti-Protease- Protease Balance in Alpha-1 Antitrypsin Deficiency, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2010; 9 (4) . https://dx.doi.org/10.2174/1871523011009040314
DOI https://dx.doi.org/10.2174/1871523011009040314 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Small Artery Remodeling in Obesity and Insulin Resistance
Current Vascular Pharmacology Role of Micronutrients on Subclinical Atherosclerosis Micronutrients in Subclinical Atherosclerosis
Current Pharmaceutical Design A Murine Model of Vasculitis Induced by Fungal Polysaccharide
Cardiovascular & Hematological Agents in Medicinal Chemistry Angiogenesis as Risk Factor for Plaque Vulnerability
Current Pharmaceutical Design Modelling the Neurovascular Unit and the Blood-Brain Barrier with the Unique Function of Pericytes
Current Neurovascular Research Imaging Patterns of Cardiovascular Involvement in Mixed Connective Tissue Disease Evaluated by Cardiovascular Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued) Viral Encephalitis: Current Treatments and Future Perspectives
Central Nervous System Agents in Medicinal Chemistry Dynamic Role of Microparticles in Type 2 Diabetes Mellitus
Current Diabetes Reviews Cerebrovascular Diseases in HIV-Infected Patients
Current HIV Research Cocaine and Acute Vascular Diseases
Current Drug Abuse Reviews Endothelial Expression of MHC Class II Molecules in Autoimmune Disease
Current Pharmaceutical Design Phytotherapeutic and Natural Compound Applications for Age-Related, Inflammatory and Serious Eye Ailments
Current Molecular Pharmacology Quantitative Determination and Validation of Four Phenolic Acids in <i>Salvia Miltiorrhiza</i> Bunge using <sup>1</sup>H-NMR Spectroscopy
Current Pharmaceutical Analysis Novel Adjunctive Therapies for the Treatment of Tuberculosis
Current Molecular Medicine Impact of Sex Hormone Metabolism on the Vascular Effects of Menopausal Hormone Therapy in Cardiovascular Disease
Current Drug Metabolism Cardio-Rheumatology: Cardiovascular Complications in Systemic Autoimmune Rheumatic Diseases / Is Inflammation the Common Link and Target?
Current Vascular Pharmacology Haemostatic Activation in HIV Infected Patients Treated with Different Antiretroviral Regimens
Current HIV Research Neurotuberculosis: An Overview
Central Nervous System Agents in Medicinal Chemistry Review of Endocrine Manifestations of Antiphospholid Syndrome
Current Rheumatology Reviews Biologics in Inflammatory Immune-mediated Systemic Diseases
Current Pharmaceutical Biotechnology